Investigating Immune Mechanisms in Atopic Eczema

Not Applicable

Withdrawn

• Conditions: Atopic Dermatitis
• Interventions: Procedure: Skin suction blister; Procedure: Skin biopsy; Biological: Mantoux test

• Registration Number: NCT02102841
• Lead Sponsor: University College, London

Brief Summary

The aim of this study is to investigate the mechanisms behind the immune dysfunction that occurs in atopic eczema (or atopic dermatitis).

Detailed Description

Atopic eczema is a chronic inflammatory skin disease that affects 15-20% of children and 12% of adults and leads to significant loss of quality of life. It results from a complex interaction of genetic and environmental factors, and is characterised by dysregulation of the cutaneous immune system. Specifically, in the skin of eczema patients there is a persistence of T lymphocytes (a crucial cell involved in regulating the immune system), and an overproduction of certain cytokines (signalling molecules that are essential in producing inflammatory responses).

The study intends to investigate the causes of atopic eczema by examining the number, characteristics and function of T lymphocytes in the skin and the blood of eczema patients, as well as the types of cytokine they produce. To achieve this the investigators aim to take skin biopsies, tissue fluid (from induced skin suction blisters) and blood samples from adult eczema patients and healthy controls for analysis. Additionally, in these groups a cutaneous immune response will be initiated by injecting tuberculin protein purified derivative (the Mantoux test) into the skin, to further investigate how the behaviour of T lymphocytes varies between eczema patients and healthy controls.

This research is important in view of the high prevalence of atopic eczema in the population. An improved understanding of its causes will hopefully lead to more effective treatments for this condition in future.

Study Timeline

• Study First Submitted: 2014-03-31
• Study First Submitted QC: 2014-03-31
• Study First Posted: 2014-04-03
• Study Start: 2014-05
• Primary Completion: 2017-05
• Study Completion: 2017-05
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-27
• Last Update Posted: 2021-04-30

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• History of atopic dermatitis (according to United Kingdom Working Party's diagnostic criteria)
• Previous Bacillus Calmette-Guerin vaccination

Exclusion Criteria

• Unable to give written informed consent
• Previous history of hypersensitivity to local anaesthetic (for skin biopsy) or tuberculin PPD (for skin test)
• Pregnancy or breast feeding
• History of tuberculosis
• Recent infection or immunisation (within last month)
• Known immunodeficiency e.g. HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
• Systemic steroids within the last month or any other immunosuppressive medications (eg. methotrexate, ciclosporin or azathioprine) within the previous 3 months
• Phototherapy within the previous 28 days
• Treatment with potent topical corticosteroids or tacrolimus ointment within the previous 7 days
• Significant co-morbidity (diabetes, renal failure, liver failure, heart failure)
• On warfarin or known bleeding disorder
• History of neoplasm in last 10 years (not including basal cell carcinoma)
• Previous keloid scarring

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Skin suction blister	Skin suction blister	Skin suction blister induced on forearm
Mantoux, skin biopsy, suction blister	Skin suction blister	0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
Skin biopsy	Skin biopsy	5mm skin punch biopsy on forearm
Mantoux, skin biopsy, suction blister	Skin biopsy	0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
Mantoux, skin biopsy, suction blister	Mantoux test	0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.

Primary Outcome Measures

Name	Time	Method
Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers	Up to 14 days

Trial Locations

Locations (1)

Royal Free London NHS Foundation Trust; 🇬🇧 London, United Kingdom